--- title: | Fact Sheets (2) description: Fact Sheets | (2) --- [![Cyprotex | The Leading ADME-Tox Specialist](https://news.cyprotex.com/hs-fs/hubfs/cyprotex%20logo.png?width=224&height=62&name=cyprotex%20logo.png "Cyprotex | The Leading ADME-Tox Specialist")](https://www.cyprotex.com/) # Science Pool ## [BSL3 High Throughput Screening Capabilities Fact Sheet](https://news.cyprotex.com/sciencepool/bsl3-high-throughput-screening-capabilities-fact-sheet) Posted by [Evotec](https://news.cyprotex.com/sciencepool/author/evotec) on Mar 8, 2022 5:05:24 PM With more then 15 years of screening experience in anti-infectives, including antibacterials and antivirals, Evotec's medium throughput and high throughput screening expertise extends to BSL2+ and BSL3 containment level.  [DOWNLOAD NOW](https://news.cyprotex.com/hubfs/Sciencepool/Fact%20sheets/Evotec%20Fact%20Sheets/bsl3-hts-capabilities-fact-sheet.pdf) 0 Comments [Click here to read/write comments](https://news.cyprotex.com/sciencepool/bsl3-high-throughput-screening-capabilities-fact-sheet#comments-listing) Tags: [Fact Sheets](https://news.cyprotex.com/sciencepool/tag/fact-sheets), [Hit & Target ID/Validation](https://news.cyprotex.com/sciencepool/tag/hit-target-id-validation), [Anti-Infectives](https://news.cyprotex.com/sciencepool/tag/anti-infectives) ## [E.SOLVE: Solving Bioavailability Challenges Fact Sheet](https://news.cyprotex.com/sciencepool/e-solve-bioavailability-challenges-fact-sheet) Posted by [Evotec](https://news.cyprotex.com/sciencepool/author/evotec) on Mar 2, 2022 1:37:10 PM ![RZ_E_SOLVE-Logo+Tagline_211004_Screen_Blue-png](https://news.cyprotex.com/hs-fs/hubfs/RZ_E_SOLVE-Logo+Tagline_211004_Screen_Blue-png.png?width=259&name=RZ_E_SOLVE-Logo+Tagline_211004_Screen_Blue-png.png) E.SOLVE is Evotec's solution to accelerate your journey to the clinic supporting your formulation strategy as early as possible from discovery to market approval. Download this fact sheet to learn more about how E.SOLVE's full range of approaches improve solubilization and bioavailability to ensure that your API can progress through the drug discovery development pipeline faster. [DOWNLOAD](https://news.cyprotex.com/hubfs/Sciencepool/Fact%20sheets/Evotec%20Fact%20Sheets/Evotec-E.SOLVE_Factsheet.pdf) 0 Comments [Click here to read/write comments](https://news.cyprotex.com/sciencepool/e-solve-bioavailability-challenges-fact-sheet#comments-listing) Tags: [IND Enabling](https://news.cyprotex.com/sciencepool/tag/ind-enabling), [Fact Sheets](https://news.cyprotex.com/sciencepool/tag/fact-sheets), [Formulation & CMC](https://news.cyprotex.com/sciencepool/tag/formulation-cmc), [Toxicology & Safety](https://news.cyprotex.com/sciencepool/tag/toxicology-safety) ## [Regulated ADMET Services Fact Sheet](https://news.cyprotex.com/sciencepool/pcd-regulated-admet-fact-sheet) Posted by [Evotec](https://news.cyprotex.com/sciencepool/author/evotec) on Mar 2, 2022 1:34:27 PM Download this fact sheet to learn more about our regulatory ADMET services including: - Full support of development projects to fulfill and anticipate regulatory requirements - Accelerated development process with a full vision through all drug development phases up to filing - Dynamic team of expert scientists capable of handling projects of any complexity in regulated environment - Full integration with in-house bioanalytical and safety assessment groups - Tailored studies and programs based on specific client needs [DOWNLOAD](https://news.cyprotex.com/hubfs/Sciencepool/Fact%20sheets/Evotec%20Fact%20Sheets/factsheet-pcd-regulated-admet.pdf) 0 Comments [Click here to read/write comments](https://news.cyprotex.com/sciencepool/pcd-regulated-admet-fact-sheet#comments-listing) Tags: [Fact Sheets](https://news.cyprotex.com/sciencepool/tag/fact-sheets), [ADME/DMPK](https://news.cyprotex.com/sciencepool/tag/adme-dmpk), [IND Enabling Studies/Preclinical Development](https://news.cyprotex.com/sciencepool/tag/ind-enabling-studies-preclinical-development), [Toxicology & Safety](https://news.cyprotex.com/sciencepool/tag/toxicology-safety) ## [INDiGO-Select Fact Sheet](https://news.cyprotex.com/sciencepool/indigo-select-fact-sheet) Posted by [Evotec](https://news.cyprotex.com/sciencepool/author/evotec) on Mar 2, 2022 1:34:15 PM Learn more about how our INDiGO-*Select* services help in profiling and selecting your optimal clinical development candidate with: - Enhanced quality profile, speed of delivery, and probability of success of clinical candidates - Early identification of developability gaps and liabilities in selection process, enabling thorough de-risking of your candidate with flexible advanced lead optimization approaches - Managed by skilled discovery scientists and complemented by experienced drug development experts in CMC and preclinical development all under one roof [DOWNLOAD](https://news.cyprotex.com/hubfs/Sciencepool/Fact%20sheets/Evotec%20Fact%20Sheets/indigo-select-fact-sheet.pdf) 0 Comments [Click here to read/write comments](https://news.cyprotex.com/sciencepool/indigo-select-fact-sheet#comments-listing) Tags: [INDiGO](https://news.cyprotex.com/sciencepool/tag/indigo), [Fact Sheets](https://news.cyprotex.com/sciencepool/tag/fact-sheets), [IND Enabling Studies/Preclinical Development](https://news.cyprotex.com/sciencepool/tag/ind-enabling-studies-preclinical-development), [Toxicology & Safety](https://news.cyprotex.com/sciencepool/tag/toxicology-safety), [Clinical Development](https://news.cyprotex.com/sciencepool/tag/clinical-development) ## [Clinical Services Fact Sheet](https://news.cyprotex.com/sciencepool/clinical-services-fact-sheet) Posted by [Evotec](https://news.cyprotex.com/sciencepool/author/evotec) on Mar 2, 2022 1:12:17 PM Learn more about our clinical services platform including: - Fully integrated drug development services supporting preclinical and clinical needs, up to regulatory approval and commercial phases - Clinical supply suitable from First in Human to Phase III, fully GMP-compliant and with capacity to handle active ingredients classified up to OEB5 (OEL>0.5 µg/m³) - Additional capabilities such as API, formulation development, sample management, PK and statistical analyses, and metabolism [DOWNLOAD](https://news.cyprotex.com/hubfs/Sciencepool/Fact%20sheets/Evotec%20Fact%20Sheets/clinical-services-fact-sheet.pdf) 0 Comments [Click here to read/write comments](https://news.cyprotex.com/sciencepool/clinical-services-fact-sheet#comments-listing) Tags: [INDiGO](https://news.cyprotex.com/sciencepool/tag/indigo), [Fact Sheets](https://news.cyprotex.com/sciencepool/tag/fact-sheets), [IND Enabling Studies/Preclinical Development](https://news.cyprotex.com/sciencepool/tag/ind-enabling-studies-preclinical-development), [Clinical Development](https://news.cyprotex.com/sciencepool/tag/clinical-development) ## [Abuse Liability Fact Sheet](https://news.cyprotex.com/sciencepool/abuse-liability-assessment-fact-sheet) Posted by [Evotec](https://news.cyprotex.com/sciencepool/author/evotec) on Feb 10, 2022 11:30:19 AM Learn more about our abuse liability services including: - Compound characterization - Pharmacological assessment - Preclinical Behavioral studies - Integration within a multidisciplinary full-scope clinical-enabling program with chemistry, pharmacology, DMPK, safety assessment, regulatory and clinical support, all driven by our drug development experts [DOWNLOAD](https://news.cyprotex.com/hubfs/Sciencepool/Fact%20sheets/Evotec%20Fact%20Sheets/abuse-liability-fact-sheet.pdf) 0 Comments [Click here to read/write comments](https://news.cyprotex.com/sciencepool/abuse-liability-assessment-fact-sheet#comments-listing) Tags: [INDiGO](https://news.cyprotex.com/sciencepool/tag/indigo), [Fact Sheets](https://news.cyprotex.com/sciencepool/tag/fact-sheets), [IND Enabling Studies/Preclinical Development](https://news.cyprotex.com/sciencepool/tag/ind-enabling-studies-preclinical-development) ## [INDiGO: Fastest Route to the Clinic Fact Sheet](https://news.cyprotex.com/sciencepool/fastest-route-to-the-clinic-fact-sheet) Posted by [Evotec](https://news.cyprotex.com/sciencepool/author/evotec) on Feb 10, 2022 11:16:44 AM Learn more about INDiGO and Evotec's integrated preclinical development capabilities to de-risk and accelerate IND-enabling programs: - Typically, drug candidates can be advanced from candidate selection to IND-submission in 48–52 weeks - Our experienced team not only executes R&D projects, but also proactively contributes to your scientific strategy - Clients can either opt for the full INDiGO platform or selected preclinical development and CMC components [DOWNLOAD](https://news.cyprotex.com/hubfs/Sciencepool/Fact%20sheets/Evotec%20Fact%20Sheets/Factsheet_Evotec_INDiGO+pre-clinicalUpdated.pdf) 0 Comments [Click here to read/write comments](https://news.cyprotex.com/sciencepool/fastest-route-to-the-clinic-fact-sheet#comments-listing) Tags: [pre-clinical development](https://news.cyprotex.com/sciencepool/tag/pre-clinical-development), [INDiGO](https://news.cyprotex.com/sciencepool/tag/indigo), [Fact Sheets](https://news.cyprotex.com/sciencepool/tag/fact-sheets), [IND Enabling Studies/Preclinical Development](https://news.cyprotex.com/sciencepool/tag/ind-enabling-studies-preclinical-development) ## [Pathology, Necropsy and Histology Fact Sheet](https://news.cyprotex.com/sciencepool/pathology-necropsy-and-histology-fact-sheet) Posted by [Evotec](https://news.cyprotex.com/sciencepool/author/evotec) on Feb 10, 2022 11:06:45 AM Learn more about our pathology services including: - GLP certification with highest quality standards and an impeccable regulatory inspection history - Unparalleled flexibility with all capabilities in-house and under one roof - ACVP/DECVP, MRCPATH, DECLAM, DECVCP qualified pathologists/clinical pathologists [DOWNLOAD](https://news.cyprotex.com/hubfs/Sciencepool/Fact%20sheets/Evotec%20Fact%20Sheets/factsheet-Evotec-pathologyUpdated.pdf) 0 Comments [Click here to read/write comments](https://news.cyprotex.com/sciencepool/pathology-necropsy-and-histology-fact-sheet#comments-listing) Tags: [Pathology](https://news.cyprotex.com/sciencepool/tag/pathology), [Fact Sheets](https://news.cyprotex.com/sciencepool/tag/fact-sheets), [IND Enabling Studies/Preclinical Development](https://news.cyprotex.com/sciencepool/tag/ind-enabling-studies-preclinical-development) ## [Safety Assessment Fact Sheet](https://news.cyprotex.com/sciencepool/safety-assessment-fact-sheet) Posted by [Evotec](https://news.cyprotex.com/sciencepool/author/evotec) on Feb 10, 2022 10:01:32 AM Learn more about our safety assessment services including: - Toxicology core capabilities - Safety pharmacology (GLP) studies - Genetic toxicology (GLP) studies - Additional capabilities such as bioanalytical method development and GLP validation, DMPK, immunoassays, immunogenicity testing, immunotoxicology assays [DOWNLOAD](https://news.cyprotex.com/hubfs/Sciencepool/Fact%20sheets/Evotec%20Fact%20Sheets/factsheet-Evotec-safety-assessmentUpdated.pdf) 0 Comments [Click here to read/write comments](https://news.cyprotex.com/sciencepool/safety-assessment-fact-sheet#comments-listing) Tags: [INDiGO](https://news.cyprotex.com/sciencepool/tag/indigo), [Fact Sheets](https://news.cyprotex.com/sciencepool/tag/fact-sheets), [ADME/DMPK](https://news.cyprotex.com/sciencepool/tag/adme-dmpk), [IND Enabling Studies/Preclinical Development](https://news.cyprotex.com/sciencepool/tag/ind-enabling-studies-preclinical-development), [Toxicology & Safety](https://news.cyprotex.com/sciencepool/tag/toxicology-safety) ## [Regulated LC/MS Bioanalysis Fact Sheet](https://news.cyprotex.com/sciencepool/regulated-lc-ms-bioanalysis-fact-sheet) Posted by [Evotec](https://news.cyprotex.com/sciencepool/author/evotec) on Dec 21, 2021 1:56:16 PM Learn more about Evotec's regulated LC/MS bioanalysis capabilities and expertise including: - High quality service across all phases of pre-clinical and clinical drug development in compliance with GLP and GCP regulations - More than 25 years of experience to perform LC/MS activities in a regulated environment - Extensive bioanalytical method development expertise to meet the most demanding and challenging client needs - Multidisciplinary collaboration enabling integrated solutions to accelerate the drug development process [DOWNLOAD](https://news.cyprotex.com/hubfs/Sciencepool/Fact%20sheets/Evotec%20Fact%20Sheets/regulated-lc-ms-bioanalysis.pdf) 0 Comments [Click here to read/write comments](https://news.cyprotex.com/sciencepool/regulated-lc-ms-bioanalysis-fact-sheet#comments-listing) Tags: [Fact Sheets](https://news.cyprotex.com/sciencepool/tag/fact-sheets), [Proteomics, Metabolomics & Biomarkers](https://news.cyprotex.com/sciencepool/tag/proteomics-metabolomics-biomarkers), [IND Enabling Studies/Preclinical Development](https://news.cyprotex.com/sciencepool/tag/ind-enabling-studies-preclinical-development), [Sample Management](https://news.cyprotex.com/sciencepool/tag/sample-management) [Previous](https://news.cyprotex.com/sciencepool/tag/fact-sheets/page/1) [All posts](https://news.cyprotex.com/sciencepool/all) [Next](https://news.cyprotex.com/sciencepool/tag/fact-sheets/page/3)